



DISCLOSURE OF FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES

**Internal Medicine Grand Rounds
Friday, January 27, 2023**

***Teaching the Old Dog New Tricks: Efforts to Reform Clinical Trial Design
and Conduct***

**David Gerber, M.D.
Professor of Internal Medicine
Division of Hematology & Oncology
Department of Internal Medicine**

It is the policy of the CME Office at The University of Texas Southwestern Medical Center to ensure balance, independence, objectivity, and scientific rigor in all directly sponsored or jointly provided educational activities. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and independence in Accredited Continuing Education, all persons in the position to control the content of an education activity are required to disclose all financial relationships in any amount occurring within the past 24 months with any ineligible company (any entity whose primary business is producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). UT Southwestern also considers ineligible those companies producing, marketing, selling, re-selling, or distributing healthcare products in development for future use on patients, such as healthcare product research companies. All reported financial relationships with ineligible companies are reviewed for relevancy and then mitigated through a content review process prior to the activity (where applicable).

The following is a listing of all individuals that contributed to the educational content of this activity and any reported financial relationships within the last 24 months:

NAME	ROLE	RELATIONSHIP	COMPANY
Thomas J. Wang, M.D.	Course Director	Intellectual Property	Biomarkers of heart and related diseases (pending patents); Imara – PDE9 inhibitors
Salahuddin Kazi, M.D.	Course Director	Grant or Contract; Travel; Spouse or Partner	Arthritis Foundation; American Board of Internal Medicine; Sanofi Genzyme/Regeneron
David Gerber, M.D.	Speaker	Grant or Contract; Stock; Independent Contractor	Karyopharm; BerGenBio; AstraZeneca; Sagimet; Gilead; Catalyst Therapeutics; Janssen; Sanofi; Regeneron
Natalie Bavli, M.D.	Peer Reviewer	None	N/A
Deanna Franklin	Planner	None	N/A